Skip to main content
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. logo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. — Investor Relations & Filings

Ticker · 1541 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 1,170 across all filing types
Latest filing 2026-01-12 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1541

About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

http://www.immuneonco.com

ImmuneOnco Biopharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of immuno-oncology therapies. The company focuses on developing cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and actively eradicate malignant cells. ImmuneOnco is distinguished by its capability to systematically utilize both the innate and adaptive immune systems, positioning it to overcome the limitations of current T-cell based immunotherapies. By leveraging this dual approach, the company aims to address significant unmet medical needs associated with low response rates, drug resistance, and recurrence in various cancer indications.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) FOR ATHEROSCLEROSIS
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from ImmuneOnco Biopharmaceuticals regarding the NMPA approval for a clinical trial of their product, IMM01. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding business development that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-01-12 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it details changes in share capital and issued shares, it falls under the category of share capital changes and regulatory reporting. Given the specific nature of the HKEX Monthly Return, it is best classified as a Share Issue/Capital Change (SHA) filing.
2026-01-07 English
DELAY IN DESPATCH OF CIRCULAR
Regulatory Filings Classification · 1% confidence The document is a short announcement regarding a delay in the dispatch of a circular related to a loan agreement and listing rule compliance. It does not contain the actual financial report or the circular itself, but rather serves as a regulatory notification of a timeline change. Since it is a regulatory announcement that does not fit into specific categories like M&A or dividend notices, it falls under the general regulatory filing category.
2026-01-06 English
INSIDE INFORMATION - IMMUNEONCO TO REGAIN GLOBAL RIGHTS TO IMM2510 AND IMM27M
Regulatory Filings Classification · 1% confidence The document is an official announcement regarding the termination of a License and Collaboration Agreement and the subsequent reversion of global rights for specific drug candidates (IMM2510 and IMM27M) to the company. This constitutes a significant corporate development related to business strategy and asset management. It does not fit into specific categories like financial reports, dividend announcements, or director dealings. As it is a regulatory announcement regarding material inside information under the Hong Kong Stock Exchange Listing Rules, it is best classified as a Regulatory Filing (RNS).
2026-01-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX for listed companies to report movements in securities, share capital, and share options on a monthly basis. It does not fit into specific categories like '10-K' (Annual Report) or 'ER' (Earnings Release), and since it is a recurring regulatory disclosure of share movements, it is best classified as a Regulatory Filing (RNS).
2026-01-02 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 DECEMBER 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'POLL RESULTS OF THE ANNUAL GENERAL MEETING' and provides a detailed breakdown of the voting results for various resolutions proposed at the AGM held on 30 December 2025. It explicitly lists the number of votes for and against each resolution and confirms that all resolutions were passed. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2025-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.